about
Activation of multiple proto-oncogenic tyrosine kinases in breast cancer via loss of the PTPN12 phosphataseStem-like features of cancer cells on their way to metastasisRecent advances in the biology of human circulating tumour cells and metastasisGenome profiling of chronic myelomonocytic leukemia: frequent alterations of RAS and RUNX1 genes.Co-expression of HER2 and HER3 receptor tyrosine kinases enhances invasion of breast cells via stimulation of interleukin-8 autocrine secretion.Inflammatory breast cancer: a model for investigating cluster-based dissemination.Circulating tumor cell clusters are oligoclonal precursors of breast cancer metastasis.Single-cell RNA sequencing identifies extracellular matrix gene expression by pancreatic circulating tumor cellsAntagonism of EGFR and HER3 enhances the response to inhibitors of the PI3K-Akt pathway in triple-negative breast cancer.Cancer therapy. Ex vivo culture of circulating breast tumor cells for individualized testing of drug susceptibility.A microfluidic device for label-free, physical capture of circulating tumor cell clusters.Tunable nanostructured coating for the capture and selective release of viable circulating tumor cellsEpithelial protein-tyrosine phosphatase 1B contributes to the induction of mammary tumors by HER2/Neu but is not essential for tumor maintenance.A tunable delivery platform to provide local chemotherapy for pancreatic ductal adenocarcinomaExpression of β-globin by cancer cells promotes cell survival during blood-borne dissemination.Tyrosine phosphatase SHP2 promotes breast cancer progression and maintains tumor-initiating cells via activation of key transcription factors and a positive feedback signaling loop.Tyrosine phosphatase SHP2 increases cell motility in triple-negative breast cancer through the activation of SRC-family kinases.Tyrosine phosphatase PTPα contributes to HER2-evoked breast tumor initiation and maintenance.Mammary tumor formation and metastasis evoked by a HER2 splice variant.Memo is a copper-dependent redox protein with an essential role in migration and metastasis.Microfluidic isolation of platelet-covered circulating tumor cells.SHP2 regulates proliferation and tumorigenicity of glioma stem cells.AR Expression in Breast Cancer CTCs Associates with Bone Metastases.Genomic Instability Is Induced by Persistent Proliferation of Cells Undergoing Epithelial-to-Mesenchymal Transition.Beyond Enumeration: Functional and Computational Analysis of Circulating Tumor Cells to Investigate Cancer Metastasis.On the road to combinations of targeted therapies: PPM1H phosphatase as a suppressor of trastuzumab resistance.Cancer Diagnosis Using a Liquid Biopsy: Challenges and Expectations.Denosumab treatment is associated with the absence of circulating tumor cells in patients with breast cancerCirculating Tumor Cell Clustering Shapes DNA Methylation to Enable Metastasis SeedingEndothelial cell-derived nidogen-1 inhibits migration of SK-BR-3 breast cancer cellsFluctuating numbers of circulating tumor cells in cancer patients and the meaning of zero countsDeregulation of ribosomal protein expression and translation promotes breast cancer metastasisCirculating Tumor Cell-Neutrophil Tango along the Metastatic ProcessComputational Analysis of DNA and RNA Sequencing Data Obtained from Liquid BiopsiesDetection of circulating tumour cell clusters in human glioblastomaNeutrophils escort circulating tumour cells to enable cell cycle progressionTo Be Taken in Count: Prostatic Tumor Cells Break Free upon Needle BiopsyCell-free DNA analysis in healthy individuals by next-generation sequencing: a proof of concept and technical validation studyMicromanipulation of Circulating Tumor Cells for Downstream Molecular Analysis and Metastatic Potential AssessmentE-cadherin is required for metastasis in multiple models of breast cancer
P50
Q24294831-0D5E9F95-A5EA-4DBF-9327-5FEFF76AD32FQ26741641-B22E2CA6-14F6-4BBC-8DDC-D63E1EF38B51Q28070120-1B55DDE3-CB5C-4B15-8B2D-0FF2A7FD92C1Q33377270-4C143E7A-7665-4477-AB8B-4BA1219AB267Q33739262-134EAB59-90CD-42F8-B2DA-BE9A04E79B22Q33767606-50884675-CB01-46D8-95A8-6EEF34DA0526Q34111187-00E81EE4-1FA3-46A5-9F2B-CE60894BACD3Q34502783-527B03E6-7F4F-427E-8542-2E985D7F45B1Q34813272-54CAF762-4CB6-4871-B489-9935D69B6AE3Q35174681-3B2AE620-3DC9-4020-B685-97528A74B0FFQ35812039-819E3D92-7743-4707-8302-7DB7B6D782A4Q35820728-F01352D2-3B08-4A84-9CEB-8DAD02912BABQ36634268-9312805C-1BB8-4435-960D-1C39970DC897Q36848514-6CC660F7-C406-46CC-8348-04830183A4B2Q37660683-843299EF-BE5D-4D92-BF75-BC58336069EAQ38327185-2337FA0E-1D2E-4CD1-8029-666BFB3B653CQ38984571-EB3044EC-AFCC-4303-AB96-AB34670C5294Q39210889-D5DB23A0-8DFD-4F2B-9411-8A12AE7E3D3CQ45659107-C0859B8B-F639-4C90-9F1F-1E289833B5BAQ46881176-9A0D0017-386A-4062-9C33-BF606BCDE0A8Q47653261-4B4DF68C-BC0B-437E-AE99-47270A60C4BBQ47885098-6401D643-0487-4A73-815C-BD88A5D46A96Q49913672-5A39D7D5-7AC4-4D51-A4A8-99855B010145Q50231325-36494253-2597-40D4-A0BE-A90941AA15D5Q53838776-751078AE-1FC3-45F9-B5CC-B35BDD5DFF5AQ54510902-E178DC42-9691-4A5D-964C-24949FDF0F4FQ55692870-E429A0FF-C1FA-4775-843C-2A4DA1A073ABQ59329877-BF7F8A07-3BFE-4779-A0B0-AFC60ED7CB4FQ61797489-5128B0B4-DF62-4D5C-BF67-181D40EDE934Q64075139-AD998257-347C-48C2-AFBC-42D9DEA91C6AQ64120407-6EE6C09E-70D5-4EFE-A5DB-7786797C3F1DQ89582237-966EA6BC-B391-48BD-B389-9FA8D1A42593Q90131391-FF837015-62B6-4B97-849D-B21A3BC8683EQ90664808-AC1D503E-4E3E-44D0-A87B-4D70CB2C4255Q90672790-29702A20-862F-4457-AB2D-104E5D7E7AE7Q91387375-BBA36E8F-B9F6-4158-A1A2-3834CA9BEF50Q91766403-72FE8E83-B418-4F45-B38A-2495992F58B6Q91809276-02D14BBB-04CE-402D-A8DE-7E1A158D9CAFQ92485216-080EF5B0-0064-410E-A843-5F6394B75860Q93107332-7BD35119-02A3-4A8C-BAAF-3B0D144D46D5
P50
description
hulumtues
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Nicola Aceto
@ast
Nicola Aceto
@en
Nicola Aceto
@es
Nicola Aceto
@nl
Nicola Aceto
@sl
type
label
Nicola Aceto
@ast
Nicola Aceto
@en
Nicola Aceto
@es
Nicola Aceto
@nl
Nicola Aceto
@sl
prefLabel
Nicola Aceto
@ast
Nicola Aceto
@en
Nicola Aceto
@es
Nicola Aceto
@nl
Nicola Aceto
@sl
P1053
O-2484-2014
P106
P21
P31
P3829
P496
0000-0001-9579-6918